Intra-abdominal Pressure Measurement Devices Market Share and Growth Factors Covid-19 Impact Analysis 2021–2027 | BD, C2DX, Inc, and Medline Industries

 

The global intra-abdominal pressure measuring devices market was worth USD 108.2 million in 2019, with a compound annual growth rate (CAGR) of 7.9% projected from 2020 to 2027. The high prevalence of intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS) among ICU patients, as well as the use of technologically improved products, are believed to be the key reasons. Intra-abdominal hypertension is defined as a blood pressure of more than 12 millimeters of mercury, which is the pressure at which organ dysfunction develops. For severely unwell people, the normal intra-abdominal pressure (IAP) should be between 5-7 mmHg.

The global intra-abdominal pressure measuring devices market was worth USD 108.2 million in 2019, with a compound annual growth rate (CAGR) of 7.9% projected from 2020 to 2027.

The main cause of IAH is an excess of intra-abdominal volume in the abdominal cavity. Furthermore, patients with acute abdominal syndromes such as intestinal perforation, peritonitis, ileus, acute pancreatitis, or trauma are more likely to have increased IAP. IAPMD is a tool that measures IAP to identify those who are at risk of IAH/ACS.

Patients in intensive care units around the world have a high prevalence of IAH/ACS. The presence of IAH and ACS is linked to a higher risk of mortality and morbidity. Tissue hypoperfusion is caused by an increase in intra-abdominal pressure, which can result in reduced hepatic blood flow, numerous organ dysfunction syndromes, respiratory failure, increased intracranial pressure, and renal failure. According to a report published in the Critical Care Medicine Journal in 2019, 38-45 percent of patients treated in ICU settings develop intra-abdominal hypertension. As a result, the market is primarily driven by rising demand for intra-abdominal pressure measurement devices for the early detection and treatment of IAH and ACS. In recent years, countries such as The United States and Canada have seen an increase in ICU admissions and urological illnesses such as interstitial cystitis, bladder cancer, prostate cancer, and bowel syndrome. According to the Society of Critical Care Medicine (SCCM), around 5.0 million patients are admitted to ICUs in the United States each year for invasive or intensive monitoring. Furthermore, according to Statistics 2020 from the Canadian Cancer Society, 23,300 males will be diagnosed with prostate cancer in 2020. As a result of the rising prevalence of IAH and ACS among ICU patients, as well as associated illnesses, the market for intra-abdominal pressure measurement devices are expected to rise over the forecast period.

In 2019, North America dominated the market with a 60.2 percent share. This is due to the region's well-established healthcare facilities, increased government initiatives, and an increase in the number of ICU admissions. Furthermore, the presence of major key players such as BD, C2DX, Inc, and Medline Industries, as well as the availability of technologically improved products, are all helping to the growth of the intra-abdominal pressure measuring devices market in the area.

Due to variables such as an aging population, a large population base, and unmet needs for IAH diagnosis and treatment in this area, Asia Pacific is predicted to expand at the highest CAGR of 8.8% from 2020 to 2027. Furthermore, advancements in the clinical development framework of developing countries like Japan, India, and China are projected to help to the expansion of the market for in vitro diagnostics.